Form D · Biotechnology
Immuneering Corp
Cambridge, MA · CIK 0001790340
Offering snapshot reported Sep 9, 2025 · SEC filing
- Reported sold
- $25M Offering amount: $25M
- Investors reported
- 9 Form D · investor count
- Minimum accepted
- Not reported Reported outside-investor minimum
- First sale
- Aug 26, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 9, 2025 | Initial | $24,998,919 | No comparison | 9 | SEC filing |
| Jan 5, 2021 | Initial | $37,199,807 | No comparison | 39 | SEC filing |
| Jan 27, 2020 | Amendment | $20,000,003 | $5,026,248vs Oct 4, 2019 | 67 | SEC filing |
| Oct 4, 2019 | Initial | $14,973,755 | No comparison | 49 | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- Not reported
- Duration over one year
- Not reported
- Business combination
- Not reported
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-557113
Source: Form D, filed Sep 9, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Robert J. Carpenter | Director |
| Peter Feinberg | Director |
| Diana F. Hausman | Director |
| Laurie B. Keating | Director |
| Joseph Kekst | Director |
| Andrew Phillips | Director |
| Thomas J. Schall | Director |
| Benjamin J. Zeskind | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
245 Main Street, Second Floor
Cambridge, MA, 02142
Cambridge, MA, 02142